financetom
IXHL
financetom
/
Healthcare
/
IXHL
All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities
Incannex Healthcare LimitedIXHL
USD
- At close
USD
- Until the end
The complete list of US stocks
1D
5D
1M
1Y
5Y
MAX
Overview >
% Change
Description >

Incannex Healthcare Inc., a clinical stage pharmaceutical development company, engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies.

It develops products for the treatment of obstructive sleep apnoea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, pain, and other indications.

The company offers APIRx-1801, an ultrapure tetrahydrocannabinol; APIRx-1802, an ultrapure CBD; and APIRx-1803, an ultrapure cannabigerol.

It also develops IHL-42X, which has completed Phase IIb clinical trial for obstructive sleep apnea; Psi-GAD that is in Phase IIa clinical trial for generalized anxiety disorder; MedChew Dronabinol, which has completed Phase Ia clinical trial for nausea and vomiting in chemotherapy; CanChew Plus that has completed Phase IIa clinical trial for irritable bowel syndrome; APIRx-1601, which has completed Phase IIa clinical trial for vitiligo; APIRx-1602 skin that has completed Phase IIa clinical trial for psoriasis; and APIRx-1603, which has completed Phase IIa clinical trial for atopic dermatitis.

In addition, its product portfolio includes IHL-675A for inflammatory lung disease, IHL-675A for rheumatoid arthritis, IHL-675A for inflammatory bowel disease, and IHL-216A for traumatic brain injury and concussion, which have completed pre-clinical trials; and MedChew 1401 for pain and spasticity in multiple sclerosis, MedChew GB for post-herpatic neuralgia, MedChew-1502 for Parkinson's disease, MedChew-1503 for dementia, MedChew RL for restless legs syndrome, APIRx 1505 Flotex for chrohn's disease, CanChew RX and SuppoCan (Suppository) for inflammatory bowel disease, CheWell for addiction of cannabis, CanQuit for tobacco smoking cessation, CanQuit O for opioid addiction, APIRx-1701 for glaucoma, suppoCan gastro for IBD, and APIRx-1702 for dry eye syndrome that are in pre-clinical trials.

Incannex Hea

Latest News >
METALS-Copper hits near one-week low on stronger dollar, growth fears
METALS-Copper hits near one-week low on stronger dollar, growth fears
Jun 19, 2025
(Rewrites, adds analyst comments and updates prices) By Ashitha Shivaprasad June 19 (Reuters) - Copper prices touched a near one-week low on Thursday and most other base metals also slipped, dragged down by a strong dollar and mounting global growth fears amid escalating tensions between Israel and Iran. The LME's three-month copper was down 0.5% at $9,608 per metric ton,...
Mars has not offered remedies to EU for kellanova deal, EU website shows
Mars has not offered remedies to EU for kellanova deal, EU website shows
Jun 19, 2025
BRUSSELS (Reuters) -Candy giant Mars has not offered remedies to EU antitrust regulators reviewing its proposed $36-billion takeover of Pringles maker Kellanova ( K ), an update on the European Commission website showed on Thursday. The deadline for Mars to offer remedies was June 18. Reuters reported on Wednesday that Mars was unlikely to offer remedies for now to address...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Elon Musk's xAI May Face 'Clean Air Act' Lawsuit Over Alleged Pollution At Memphis Data Center
Elon Musk's xAI May Face 'Clean Air Act' Lawsuit Over Alleged Pollution At Memphis Data Center
Jun 19, 2025
The data center operated by Elon Musk‘s xAI in Memphis is facing potential legal action for running a fleet of natural gas turbines without the necessary permits. What Happened: The Southern Environmental Law Center (SELC) sent a letter to xAI, threatening legal action on behalf of the NAACP. The letter accuses xAI of violating federal law by operating methane gas turbines at its South Memphis data center...
Copyright 2023-2025 - www.financetom.com All Rights Reserved